NCT05047133

Effect of Early Administration of TXA in Adult Hip Fractures

Does Early Administration of Tranexamic Acid Decrease Perioperative Blood Loss in Addition to Intraoperative Tranexamic Acid for Hip Fracture Patients?

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 170 (estimated)
• Sponsor: Ascension Health · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.

Conditions

• Postoperative Blood Loss

Interventions

Type	Name	Description
DRUG	Tranexamic acid	TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups

Timeline

• Start date: 2021-09-01
• Primary completion: 2022-07-01
• Completion: 2022-07-01
• First posted: 2021-09-16
• Last updated: 2021-09-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study